Key Highlights

  • Adjusted EPS of USD 0.26 beat the consensus estimate of USD 0.24, while GAAP diluted loss was USD 0.06.
  • Net Revenue of USD 863 million rose 10% and topped the consensus estimate of USD 817.77 million.
  • Adjusted EBITDA climbed 30% to USD 207 million as Gross Profit rose to USD 334 million from USD 274 million.
  • Full year revenue guidance rose to USD 3.15 billion to 3.25 billion from USD 3.10 billion to 3.20 billion.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) reported third quarter 2026 net revenue of USD 862.7 million, up 10% from USD 784.5 million a year earlier and above a consensus estimate of USD 817.77 million. Adjusted diluted EPS of USD 0.26 rose 53% from USD 0.17 and compared with a consensus estimate of USD 0.24. On a GAAP basis the company recorded a net loss attributable to the company of USD 22 million, or a diluted loss of USD 0.06 per share, against Net Income of USD 2 million a year earlier.

The swing to a GAAP loss reflected non-recurring Acquisition and integration costs of USD 22.3 million tied to the Kashiv acquisition, a higher tax provision and a larger share count. Adjusted EBITDA reached USD 207 million, up 30%.

Segment Growth Led by Biosimilars and Branded Products

Affordable Medicines net revenue rose 19%, driven by biosimilars, women's health patches and new launches. Specialty net revenue rose 20%, led by CREXONT, the BREKIYA autoinjector and UNITHROID. AvKARE net revenue fell 17% because of a non-recurring cardiovascular product launch in the prior year period. Gross profit increased to USD 334.1 million from USD 274.0 million, while selling, general and administrative expenses edged up to USD 139.6 million from USD 137.8 million and net interest expense eased to USD 58.9 million from USD 62.8 million.

Co-Chief Executive Officers Chirag and Chintu Patel said performance was broad based and pointed to launches across women's health patches, biosimilars, injectables such as lanreotide, CREXONT and the BREKIYA autoinjector. They added that the Kashiv integration is proceeding well.

Updated 2026 Guidance Ranges

The company raised full year net revenue guidance to USD 3.15 billion to USD 3.25 billion, adjusted EBITDA guidance to USD 800 million to USD 815 million from USD 750 million to USD 780 million, and adjusted diluted EPS guidance to USD 1.04 to USD 1.08 from USD 0.96 to USD 1.06. Operating Cash Flow guidance was lowered to USD 325 million to USD 375 million from USD 350 million to USD 400 million, reflecting Working Capital needs including higher inventory in key growth areas. Capital expenditures remain guided at about USD 150 million. The EPS range assumes roughly 340 million weighted average diluted shares.

Full Year Guidance Against Nine Month Actuals and Leverage

Nine month net revenue of USD 2.381 billion compares with full year guidance of USD 3.15 billion to USD 3.25 billion, and nine month adjusted EBITDA of USD 615.5 million compares with guidance of USD 800 million to USD 815 million, which leaves about USD 185 million to USD 200 million for the fourth quarter against USD 207 million in the third. Net Leverage stood at 3.9 times against 3.5 times at year end 2025, with net Debt of USD 3.07 billion against USD 2.41 billion. Cash and cash equivalents were USD 157.4 million against USD 282.0 million. Guided operating cash flow of USD 325 million to USD 375 million compares with USD 350 million to USD 400 million once opioid settlement costs of about USD 36 million and Kashiv costs of about USD 40 million are excluded.